GeoVax Targets 2027 Phase 2 Neoadjuvant Trial for Gedeptin with ICIs
GeoVax plans to initiate a Phase 2 trial of Gedeptin combined with immune checkpoint inhibitors in first-line neoadjuvant resectable locally advanced head and neck cancer in 2027 and is exploring partnerships to support development. Concurrent preclinical studies will assess Gedeptin across additional solid tumors to expand clinical indications.
1. Phase 2 Trial Plans
GeoVax is preparing to initiate a Phase 2 clinical trial in 2027 evaluating intratumoral Gedeptin with an immune checkpoint inhibitor as first-line neoadjuvant therapy in patients with resectable locally advanced head and neck cancer. This follows completed Phase 1/2 studies that demonstrated safety and provided a clinical and scientific foundation for further development.
2. Preclinical Evaluation Across Solid Tumors
In parallel, the company will advance preclinical and translational studies of Gedeptin in additional solid tumor indications to identify optimal combination settings, support expansion beyond head and neck cancer and refine future clinical strategies for broader application.
3. Partnership Strategy and Intellectual Property
GeoVax is engaging potential strategic partners to accelerate development of Gedeptin’s combination regimens, supported by an oncology advisory board and expanded intellectual property protecting its use alongside checkpoint inhibitors in evolving treatment backbones.